Axess Medica’s orthopedics care has been acquired by Capio AB
Transmedica A/S, based in Denmark, has sold Axess Medica’s orthopedics care operations to Capio AB for an undisclosed consideration.
Axess Medica’s orthopedics care operations offer specialist orthopedic and rheumatology care at Spenshult, a specialist hospital which complements existing rheumatological care facilities in Sweden.
Capio, based in Sweden, is one of Europe’s leading healthcare companies. Via its hospitals, specialist clinics and primary care units, it offers a broad range of medical, surgical and psychiatric healthcare of high quality.
Transmedica A/S, based in Denmark and majority owned by Odin Equity Partners, is a professional health care provider, which offers a broad range of services in the Scandinavian healthcare sector. The group's activities are divided into two main business units: health care personnel staffing and ownership and management of medical centers, clinics and hospitals.
Oaklins’ teams in Sweden and Denmark advised the seller in this transaction.
Talk to the deal team
Related deals
Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.
Learn moreGroupe JVS has completed an LBO with Capza and Bpifrance
The shareholders of Groupe JVS have completed an LBO with Capza and BpiFrance. Parquest sold their shares after partnering with the organization for three years. Groupe JVS’s management team will increase its ownership and remain as the majority shareholder of the group, alongside CAPZA and Bpifrance.
Learn moreCreo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Learn more